Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “Company”) today announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.

The presentation will be webcast live and accessible via the investor section of the Aurinia website, www.auriniapharma.com. A replay will also be archived on the Company website following the event.

About Aurinia

Aurinia Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company is currently developing an investigational drug, for the treatment of lupus nephritis, focal segmental glomerulosclerosis and dry eye syndrome. The Company’s head office is in Victoria, British Columbia and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200221005283/en/

Aurinia Pharmaceuticals Inc. Aktie

5,68 €
8,02 %
Ausgeprägter Aufwärtstrend bei Aurinia Pharmaceuticals Inc. mit einem Gewinn von 8,02 % heute.
Die Community ist noch unentschlossen über Aurinia Pharmaceuticals Inc. mit wenigen Einschätzungen.
Für Aurinia Pharmaceuticals Inc. ergibt sich ein positives Potenzial von 75.99%, obwohl das Kursziel von 10 € über 5.68 € liegt.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare